IDH2 inhibitors suppress the production of 2-HG that is a kind of oncometabolite in IDH2-mutant cells; AG-221 and AGI-6780 prompt demethylation of DNA and histone in IDH2-mutant cancer cells. Here, IDH2 is linked to cancer.